Transition stops development of diabetes drug

A clinical study of Transition Therapeutics’ (TSX:TTH; NASDAQ:TTHI) gastrin analogue TT-223 in combination with an Eli Lilly (NYSE: LLY) GLP-1 analogue in patients with Type 2 diabetes did not meet its efficacy endpoints and there will be no further development of TT-223. “While TT-223 had shown efficacy through development, these results indicate that it does [...]

Transition posts positive Phase 2 diabetes results

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has reported positive results with type 2 diabetic patients in a Phase 2 clinical study of its gastrin analogue, TT-223 drug. Patients who received the highest daily dose of TT-223 for 12 weeks and completed the entire study without adjusting their diabetes therapies had a “statistically significant” reduction in HbA1c of [...]